Pancreatic Cysts on Imaging: When Are They Dangerous?

Research-informed explainer — last updated April 12, 2026

If your CT scan or MRI showed a cyst on your pancreas, you are not alone — these incidental findings show up in roughly 2 to 3 percent of abdominal imaging studies and have become more common as imaging quality has improved. The overwhelming majority of pancreatic cysts found this way are benign and will never cause a problem. But a small fraction do carry meaningful cancer risk and need either close monitoring or surgery. The key to good care is distinguishing the types that need attention from the ones that can be watched less aggressively — or left alone entirely.

This explainer draws on research from four specialists in the Convene directory. Michael Goggins at Johns Hopkins is director of the Pancreatic Cancer Early Detection Laboratory and has published foundational work on the molecular biology of pancreatic cancer, including the core signaling pathways that explain why some cysts become malignant. Santhi Vege at Mayo Clinic is lead author on the Atlanta Classification of acute pancreatitis and has contributed to the AGA guideline on asymptomatic neoplastic pancreatic cysts that governs how these findings are managed. Robert Hawes at Orlando Health is a pioneer in endoscopic ultrasound techniques and established EUS-guided fine-needle aspiration as the standard method for evaluating indeterminate pancreatic lesions. Jeffrey Lee at MD Anderson helped define the criteria for borderline resectable pancreatic cancer, including the evaluation protocols used when a cyst shows worrisome features on imaging.

What a pancreatic cyst actually is

A cyst is a fluid-filled sac. In the pancreas, cysts can form for different reasons and carry very different levels of concern depending on their type. Most cysts found incidentally are either pseudocysts (which form after pancreatitis and are not pre-cancerous) or benign cystic lesions of various types. The ones that require the most attention are called mucinous neoplasms — they produce mucin and have a defined cancer risk.

The three most clinically important types of pancreatic cysts are:

Intraductal papillary mucinous neoplasms (IPMNs). These arise from the cells lining the main pancreatic duct or its branches. They are the most common incidentally found neoplastic cysts. Main duct IPMNs carry meaningfully higher cancer risk than branch duct IPMNs. The key worrisome features are connection to the main duct, the presence of solid components or "mural nodules" inside the cyst, duct dilation, and rapid growth.

Mucinous cystic neoplasms (MCNs). These almost always occur in women and are located in the body or tail of the pancreas. They do not connect to the pancreatic duct. They have a defined but lower malignancy rate than main duct IPMNs, and many guidelines recommend surgical resection if the patient is a good operative candidate.

Serous cystadenomas. These are almost always benign and are typically described on imaging as looking like a cluster of tiny cysts. They do not require surveillance unless they grow large enough to cause symptoms.

What the guidelines say

The AGA guideline on asymptomatic neoplastic pancreatic cysts — one of the key frameworks for managing incidental cyst findings — recommends that initial management be guided by cyst size, type, the presence or absence of concerning features, and patient factors including age and surgical fitness [3]. The guideline, developed with input from Santhi Vege and colleagues, takes a risk-stratified approach: not every cyst needs EUS or surgery, and not every cyst that needs surveillance needs it every year.

For small branch duct IPMNs without worrisome features, the guideline recommends MRI surveillance rather than EUS initially, with a frequency that depends on size (every year for larger cysts, every two years for smaller ones). Surgery is not recommended for these patients unless high-risk features develop.

High-risk features that shift the recommendation toward surgical evaluation include a solid component inside the cyst, a dilated main pancreatic duct (greater than 10 mm), or jaundice. Worrisome features that warrant further evaluation — typically EUS — include cysts larger than 3 cm, a thick or enhanced cyst wall, dilation of the main duct between 5 and 9 mm, a non-enhanced mural nodule, or a change in caliber of the main duct with gland atrophy.

What endoscopic ultrasound adds

When imaging is inconclusive or worrisome features are present, endoscopic ultrasound (EUS) with fine-needle aspiration is the standard next step. EUS provides much higher-resolution images of the pancreas than CT or MRI, and the needle allows fluid from inside the cyst to be sampled and analyzed.

Robert Hawes and colleagues at their institution published landmark data on EUS-FNA as a diagnostic tool for pancreatic lesions, demonstrating high sensitivity and specificity for distinguishing malignant from benign pancreatic masses [7]. A follow-up technical paper established how EUS with linear array and radial scanning endosonography could be used to characterize cystic lesions in detail [8]. Cyst fluid CEA (carcinoembryonic antigen) and cytology are the two tests most commonly run on aspirated fluid. High CEA values strongly suggest a mucinous cyst; the presence of atypical or malignant cells on cytology changes management immediately.

Understanding the cancer risk

Pancreatic cancer is among the most lethal malignancies, with a five-year survival rate of roughly 12 percent for all stages combined — primarily because most cases are caught late. Michael Goggins and colleagues have published extensively on early detection strategies, including circulating tumor DNA approaches that can detect cancer before it is visible on imaging [2]. The reason pancreatic cyst surveillance matters so much is that pancreatic adenocarcinoma has a distinct precancerous stage — particularly through the IPMN pathway — where intervention before malignant transformation can save lives [1].

The decision about when to operate is based on a risk-benefit calculation: what is the cancer risk of this specific cyst in this specific patient, and what is the operative risk for that patient? In patients who are older, have significant comorbidities, or have cysts that are small and stable with no worrisome features, watchful waiting with surveillance imaging may offer better overall outcomes than surgery. Jeffrey Lee and colleagues at MD Anderson defined the framework for evaluating borderline resectable pancreatic disease — distinguishing which lesions are appropriate for upfront surgery, neoadjuvant therapy first, or ongoing observation [9].

What to expect from surveillance

If your doctor recommends surveillance, that typically means periodic MRI (often preferred over CT because it avoids radiation and provides better soft-tissue contrast for cysts). The interval depends on cyst size and features:

• Cysts smaller than 1 cm: MRI every two years
• Cysts 1 to 2 cm: MRI annually for two years, then less frequently if stable
• Cysts 2 to 3 cm: MRI every six to 12 months, with consideration of EUS
• Cysts larger than 3 cm: EUS and likely surgical consultation

These intervals are not absolute — your gastroenterologist will weigh your cyst's specific features, your family history of pancreatic cancer, and your overall health. Pancreatitis history also matters: the Atlanta Classification framework, developed with Santhi Vege's contributions, helps distinguish cysts arising from pancreatitis complications (pseudocysts) from neoplastic cysts, which have very different implications [4].

When to seek more urgent evaluation

Most pancreatic cysts do not cause symptoms. If you develop any of the following, contact your doctor promptly rather than waiting for your next surveillance appointment:

• New onset of jaundice (yellowing of eyes or skin) or light-colored stools
• Unexplained weight loss
• New onset of diabetes in a patient with a known pancreatic cyst
• Upper abdominal pain radiating to the back
• Acute pancreatitis without a clear cause

These can indicate that a cyst has grown, changed behavior, or progressed to a more serious condition requiring immediate evaluation.

Questions to ask your doctor

• What type of cyst is this, and what does that type tell us about cancer risk?
• Does my cyst have any features right now that make it higher-risk, or is it clearly low-risk at this point?
• Should I have an EUS, or is MRI surveillance the right starting point?
• How often do I need surveillance imaging, and for how long?
• At what point would surgery be recommended, and who at this institution performs pancreatic surgery?
• Does my family history of pancreatic cancer change the recommended surveillance schedule?